Cambridge Cognition Holdings logo

COG - Cambridge Cognition Holdings Share Price

27.5p 0.0  0.0%

Last Trade - 13/12/19

Sector
Healthcare
Size
Micro Cap
Market Cap £6.65m
Enterprise Value £4.59m
Revenue £5.56m
Position in Universe 1597th / 1841
Bullish
Bearish
Unlock COG Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

COG Revenue Unlock COG Revenue

Net Income

COG Net Income Unlock COG Revenue

Normalised EPS

COG Normalised EPS Unlock COG Revenue

PE Ratio Range

COG PE Ratio Range Unlock COG Revenue

Dividend Yield Range

COG Dividend Yield Range Unlock COG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
COG EPS Forecasts Unlock COG Revenue
Profile Summary

Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 12, 2012
Public Since April 18, 2013
No. of Shareholders: n/a
No. of Employees: 73
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 24,170,093
Free Float (0.0%)
Eligible for
ISAs
SIPPs
COG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for COG
Upcoming Events for COG
Similar to COG
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.